Zhongwei Lv

Zhongwei Lv

Auto-generated profile, based on publicly available information

Zhongwei Lv

Shanghai Tenth People's Hospital 1 shanghai

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YLYan-Song Lin
Yan-Song Lin
SQShukui Qin
Shukui Qin
HYHui Yang
Hui Yang
FSFeng Shi
Feng Shi
AYAimin Yang
Aimin Yang
LLLingling Liu
Lingling Liu
Purpose: The phase II/III study of donafenib was initiated when there was no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the phase II study. We aimed to further evaluate the antitumor activity and safety of donafenib in Chinese patients with RAIR-DTC. Patients and Methods: This multicenter, double-blind, placebo-controlled, phase III study enrolled 191 patients with progressive RAIR–DTC and randomized in a ratio of 2:1 to donafenib (300 mg twice daily, n = 128) or matched placebo (n = 63). An open-label donafenib treatment period was allowed upon disease progression. The primary endpoint was progression-free survival (PFS) assessed by the independent review committee. The second endpoints include objective response rate (ORR), disease control rate (DCR), safety, etc. Results: Donafenib demonstrated prolonged median PFS over placebo [12.9 vs. 6.4 months; hazard ratio (HR), 0.39; 95% confidence interval (CI), 0.25–0.61; P < 0.0001] in Chinese patients with RAIR–DTC. Improved ORR (23.3% vs. 1.7%; P = 0.0002) and DCR (93.3% vs. 79.3%; P = 0.0044) were observed in the donafenib group over placebo. For donafenib, the most common grade ≥ 3 treatment-related adverse events (AE) included hypertension (13.3%) and hand–foot syndrome (12.5%), 42.2% underwent dose reduction or interruption, and 6.3% experienced discontinuation. Conclusions: Donafenib was well-tolerated and demonstrated clinical benefit in terms of improved PFS, ORR, and DCR in patients with RAIR-DTC. The results suggest that donafenib could be a new treatment option for patients with RAIR-DTC.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 9 depicts flow cytometric evaluations showing increased proportions of total CD45+ and CD3+ cells in H22 tumors following combination therapy.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 8 shows the in vivo safety assessment, indicating no significant pathological abnormalities in major organs or body weight changes across different treatment groups.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 7 presents the increased expression of cytokines TNF-α, IFN-γ, and IL-2 in H22 tumor tissues following PTC596 plus anti-PD1 combination therapy.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 4 demonstrates that PTC596 treatment at various doses has no significant adverse effects on mouse body weight or kidney and liver functions.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 3 displays the transcriptional profiles, including heatmaps, volcano plots, and enrichment analyses, of differentially expressed genes in PTC596-treated HepG2 and HCCLM3 cells.